UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000025936
Receipt number R000029819
Scientific Title Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial
Date of disclosure of the study information 2017/02/20
Last modified on 2023/08/07 14:02:47

No. Disposal Last modified on Item of update
1 Insert 2017/01/31 23:02:04
2 Update 2017/02/01 09:19:03 Interventions/Control_1
Key exclusion criteria
3 Update 2017/02/01 09:33:33 Last name of contact person
Last name of contact person
Email
4 Update 2017/02/01 10:12:35 Name of person sending information
Name of person sending information
Email
Institute
Institute
Organization1
Email1
5 Update 2017/02/02 16:39:02 Name of person sending information
Name of person sending information
Division name
Division name
Email
Name of primary person or sponsor
Organization
Organization
Organization
Category of Funding Organization
Date of disclosure of the study information
6 Update 2017/02/02 16:39:55 Division name
7 Update 2018/08/08 10:37:42 Recruitment status
8 Update 2018/08/08 10:40:18 Recruitment status
9 Update 2018/08/08 10:51:39 Name of person sending information
Name of person sending information
Division name
Division name
Email
10 Update 2019/02/04 13:12:06 Anticipated trial start date
11 Update 2019/08/05 10:14:36 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address
TEL

Last name of contact person

Last name of contact person
Zip code
Address
Address
TEL
Address
Address
TEL
Address1
Tel1
Organization
Organization
Address
Address
Tel
Email
12 Update 2021/02/04 12:57:22 Date of IRB
Last follow-up date
13 Update 2021/08/05 10:00:35 Email
14 Update 2022/03/25 13:19:00 Recruitment status
15 Update 2022/08/08 08:46:05 Date of closure to data entry
16 Update 2023/02/09 12:08:06 Number of participants that the trial has enrolled
Results
Results
Results date posted
Results Delayed
Results Delay Reason
Results Delay Reason
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
17 Update 2023/08/07 14:02:47 Email1
Email